Circadian genes have been considered as a possible biological mechanism for the observed relationship between circadian rhythm disruptions and increased risk of hormone-related cancers. In the current study, we investigated the relationship between circadian gene variants and prostate cancer risk and whether reducing bioavailable testosterone modifies the circadian genes-prostate cancer relationship. We ). However, we found little evidence of increased prostate cancer risk (overall or by low/high grade) associated with circadian gene variations in men of the placebo group, suggesting potential modification of genetic effects by treatment. We did not find strong evidence that circadian gene variants influenced prostate cancer risk in men who were not on finasteride treatment. There were suggestive associations between NPAS2 variants and prostate cancer risk among men using finasteride, which warrants further investigations.
workers, 4, 5 and male airline pilots [6] [7] [8] have all linked circadian rhythm disruptions to increased prostate cancer risk. Although no underlying molecular mechanism has been identified, hypotheses involving genes that regulate the endogenous circadian rhythm have been proposed. 9 The endogenous circadian rhythm has been shown to be controlled by nine known circadian genes, including aryl hydrocarbon receptor nuclear translocator-like (ARNTL), clock homolog (mouse) (CLOCK), cryptochrome 1 (CRY1), CRY2, casein kinase 1, epsilon (CSNK1E), neuronal PAS domain protein 2 (NPAS2), period 1 (PER1), PER2, and PER3. 10 Previously, only a few epidemiologic studies examined associations between circadian gene variants and prostate cancer risk, and some suggestive associations were reported. [11] [12] [13] In genome-wide association studies (GWAS), no genetic variants of circadian genes were significantly associated with prostate cancer risk. One possible reason for the inconclusive findings may be that the association between circadian genes and prostate cancer risk needs to be evaluated under an appropriate environmental exposure. One such exposure is androgens. It is well known that dihydrotestosterone (DHT), the most potent biologically active androgen in the prostate 14 that activates the androgen receptor (AR) and subsequent signaling pathways, contributes to prostate carcinogenesis. 15 Animal models
show that androgens also have a profound effect on circadian rhythms.
For instance, gonadectomy in male mice (a method for androgen ablation) lengthens the period of circadian rhythms independent of light, and these effects were reversible with androgen replacement. 16 It is unknown whether reduction in androgen exposure also influences the relationship between circadian genes, which control the endogenous circadian rhythm, and prostate cancer risk.
The Prostate Cancer Prevention Trial (PCPT) is a previously conducted, placebo-controlled randomized clinical trial that found daily treatment with 5 mg finasteride reduced the risk of prostate cancer by 25% in men without prostate cancer. 17, 18 Finasteride is an inhibitor of 5-alpha reductase, the primary enzyme that converts testosterone to DHT. Thus, the trial provided a unique opportunity to investigate whether the associations between circadian genes and prostate cancer risk differ by exposure to DHT. One other unique aspect of the PCPT study is the existing biopsy, which confirms that all the controls in the study have negative biopsy results for prostate cancer.
Herein, we report the associations between variants in circadian genes and prostate cancer stratified by the use of finasteride in the PCPT study.
| MATERIALS AND METHODS

| Study population and subject selection
The PCPT trial is registered in ClinicalTrials.gov (NCT00288106) and details of the trial have been described previously. 17 
| Circadian genes and SNP selection
We selected nine genes that are known to control the endogenous circadian rhythm, including ARNTL, CLOCK, CSNK1E, CRY1, CRY2, NPAS2, PER1, PER2, and PER3. 10 We included both putatively functional and tag SNPs. Two types of putatively functional SNPs were included:
non-synonymous polymorphisms and polymorphisms in non-coding regions that may have functional consequences due to their effects on mRNA processing or splicing. Non-synonymous SNPs were identified by the programs SIFT, 21 PolyPhen, 22 and ESEfinder included SNPs with predicted minor allele frequencies (MAF) of 5% or greater (n = 282). After genotyping, we excluded 20 SNPs from subsequent statistical analysis because their data were missing in more than 25% of the study subjects, 9 SNPs because the MAF of the SNPs was less than 5% in the participants of the study, and 13 SNPs due to deviation from Hardy-Weinberg equilibrium. Thus, a total of 240 SNPs was included for analysis in the study.
| Statistical analysis
To evaluate the relationship between circadian gene variations and prostate cancer risk (total, low-grade, and high-grade cancers), and potential modification of the relationship by treatment, we used covariate-adjusted logistic regression models stratified by treatment group. Covariates included in the statistical models included matching factors of age (continuous) and family history, as well as potential risk factor for prostate cancer including diabetes status (dichotomous), 26, 27 and BMI (continuous). 28 Analyses were conducted using SAS software 3 | RESULTS Table 1 shows selected characteristics of the PCPT participants who
were included in the current study. In the placebo group, cases, and controls were similar on the original matching factors of age at baseline and family history of prostate cancer. Cases and controls were also similar on BMI, alcohol consumption, and smoking status. Controls were more likely to have diabetes than cases (6.6% vs. 3.3%). Characteristics of individuals treated with finasteride were in general similar to those of the placebo group. Among cases included in the study, there were more high-grade cancers in the finasteride group than in the placebo group, consistent with results of the PCPT, 17 although distribution of stage of cancer between the two treatment groups were similar. reported that of 41 SNPs in the nine core circadian genes, at least one SNP in each of the nine genes was associated with prostate cancer risk (lowest P value = 0.02). 11 In a study of fatal prostate cancer using data from three cohorts with a total of 169 Caucasian cases, eight SNPs (out of 96 examined) across the core circadian genes were nominally associated with fatal prostate cancer in at least one cohort (lowest P value = 0.003). 12 However, given the P values observed, it is likely that most of the positive findings will become null after accounting for multiple comparison, which was not performed in any of the studies discussed above.
Overall, our study does not provide strong support for an association between circadian genes and prostate cancer risk, which is generally consistent with previous studies. Nevertheless, we observed a positive association between one NPAS2 gene variation Although the molecular mechanisms underlying the observed association is unclear, experimental studies have suggested that NPAS2 may interact with DHT to influence the AR-dependent signaling pathway, 30 a pathway that is thought to contribute to prostate carcinogenesis. 15 Alternatively, it is possible that our findings are due to chance, and replication of our results using a larger sample size is needed. It should also be noted that some of the tag SNPs may also be associated with genes that reside in close proximity to the circadian genes. The genomic boundaries used to define the gene are to enable the capture of genetic variation of enhancer elements that may lie outside of coding sequences. This approach in selecting tag SNPs is used in many genetic association studies. In the current study, SNPs identified in NPAS2 also lie in the region of two other genes (TBC1D8 and RPL31) based on proximity to those genes. It is not possible to determine whether the effects of the NPAS2 SNPs, if any, are related to NPAS2, other nearby genes, or both. Thus, our results should be interpreted with caution.
There are several strengths of this study. We have a more extensive coverage of SNPs (240 SNPs) than any prior studies, allowing for a more comprehensive evaluation of circadian genes and prostate cancer risk. Case-control status was determined using biopsy, which reduced the likelihood of outcome misclassification.
We are also the only epidemiologic study that examined the potential interaction between circadian genes and DHT. A major limitation of this study is the lack of replication of our positive findings in a larger population, preferably with concurrent use of finasteride. Also, this study consisted of only U.S. Caucasian men, which limited the generalizability of our results to men in other racial/ethnic groups. | 465
In conclusion, our study did not find strong evidence that circadian gene variants influence prostate cancer risk, except for one variant in the NPAS2 gene. This finding should be replicated in future large studies. 
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